# Emergent BioSolutions (EBS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/EBS
## Company Profile
- Ticker: EBS
- Exchange: NYSE
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 6.81 USD
- Market cap: 423605590.16 USD
- Last updated: 2026-10-08
## Business Overview
Emergent BioSolutions is a biodefense and specialty products company focused on public-health preparedness, vaccines, and medical countermeasures. Its business is centered on government and specialty healthcare contracts.
## Why The Stock Is Moving

As of Oct 8, 2026, EBS closed down 3.68% at $6.81. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NYSE, Emergent sits in specialty healthcare and biodefense.

## Business Model

The company depends on government contracts, product supply, and the execution of its public-health franchise.

## Landscape Position

Emergent is outside biotech proper and belongs to the biodefense and specialty-products layer.

## Future Catalysts

- Emergent BioSolutions’ catalysts are biodefense contract awards, manufacturing execution, and any update on its public-health products. The market will care about whether the company can keep its federal-defense and infectious-disease franchise stable.

## Recent News
- 2026-09-15 11:45 EST — [Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility](https://biopharmsignal.com/news/EBS/media-advisory-emergent-to-host-ribbon-cutting-ceremony-at-canton-manufacturing--a3f0d682) — Source: Emergent BioSolutions
- 2026-09-03 11:45 EST — [Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes](https://biopharmsignal.com/news/EBS/emergent-biosolutions-completes-repurchase-of-75-million-aggregate-principal-amo-e0856773) — Source: Emergent BioSolutions
- 2026-09-01 11:55 EST — [Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)](https://biopharmsignal.com/news/EBS/emergent-biosolutions-awarded-contract-modification-valued-at-approximately-24-m-f6eb19b5) — Source: Emergent BioSolutions
- 2026-08-31 11:55 EST — [Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray](https://biopharmsignal.com/news/EBS/emergent-biosolutions-awarded-government-of-canada-standing-offer-for-narcan-nas-1cc992ba) — Source: Emergent BioSolutions
- 2026-08-31 11:54 EST — [Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day](https://biopharmsignal.com/news/EBS/emergent-biosolutions-reinforces-commitment-to-opioid-overdose-education-and-pre-45dd7459) — Source: Emergent BioSolutions